CTNND2
CTNND2 (Catenin delta-2) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Oesophageal cancer, Ovarian cancer, Pancreatic ductal adenocarcinoma and 3 more.
Overview
Has a critical role in neuronal development, particularly in the formation and/or maintenance of dendritic spines and synapses. Involved in the regulation of Wnt signalling. It probably acts on beta-catenin turnover, facilitating beta-catenin interaction with GSK3B, phosphorylation, ubiquitination and degradation.
IntOGen calls it a driver in 7 cohorts (5 activating, 2 loss-of-function), covering Oesophageal Adenocarcinoma, Lung Adenocarcinoma, Lung Squamous Cell Carcinoma, Melanoma, Ovarian Epithelial Tumour, Pancreatic Adenocarcinoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · CTNND2 (Catenin delta-2) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Oesophageal cancer, Ovarian cancer, Pancreatic ductal adenocarcinoma and 3 more.
- 1 · What it is
CTNND2 (Catenin delta-2) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Oesophageal cancer, Ovarian cancer, Pancreatic ductal adenocarcinoma and 3 more.
- 2 · What goes wrong in cancer
Has a critical role in neuronal development, particularly in the formation and/or maintenance of dendritic spines and synapses. Involved in the regulation of Wnt signalling.
- 3 · How drugs use it
No product in this corpus aims at CTNND2 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
External identifiers
Sources: HGNC HGNC:2516 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q9UQB3 (protein name, function text, keywords and locations (REST API)); IntOGen CTNND2 (driver in 7 cohorts (Act 5, LoF 2); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Has a critical role in neuronal development, particularly in the formation and/or maintenance of dendritic spines and synapses. Involved in the regulation of Wnt signalling. It probably acts on beta-catenin turnover, facilitating beta-catenin interaction with GSK3B, phosphorylation, ubiquitination and degradation. Functions as a transcriptional activator when bound to ZBTB33. May be involved in neuronal cell adhesion and tissue morphogenesis and integrity by regulating adhesion molecules. Location: Nucleus; Cell junction, adherens junction; Cell projection, dendrite; Perikaryon (UniProt). Locus 5p15.2 (HGNC).
- Oesophageal cancer: IntOGen driver in 1 cohort (ESCA)
- Ovarian cancer: IntOGen driver in 1 cohort (OVT)
- Pancreatic ductal adenocarcinoma: IntOGen driver in 1 cohort (PAAD)
- Non-small-cell lung cancer: IntOGen driver in 3 cohorts (LUAD, LUSC)
- Oesophageal and junctional adenocarcinoma: IntOGen driver in 1 cohort (ESCA)
- Melanoma: IntOGen driver in 1 cohort (MEL)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 5 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 2 cohorts. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"CTNND2" OR ABSTRACT:"CTNND2" OR TITLE:"catenin delta 2" OR ABSTRACT:"catenin delta 2" OR TITLE:"Catenin delta-2" OR ABSTRACT:"Catenin delta-2" OR TITLE:"NPRAP" OR ABSTRACT:"NPRAP" OR TITLE:"GT24" OR ABSTRACT:"GT24") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CTNND2, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetNUTM1
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, IntOGen, Ovarian cancer.
- TargetZNF750
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, IntOGen, Non-small-cell lung cancer.
- TargetCANT1
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, IntOGen.
- TargetZNF208
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, IntOGen.
- TargetKAT6A
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, IntOGen, Ovarian cancer.
- TargetNUMA1
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, IntOGen.
- TargetGRM3
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, IntOGen, Melanoma.
- TargetCDX2
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, IntOGen, Melanoma.